Retrospective Kinetic Safety Evaluation of an Intravenous Micellar Excipient Platform

Detailed Description: Protocol PICO-RWE-001 I. SCIENTIFIC RATIONALE AND PLATFORM ARCHITECTURE Protocol PICO-RWE-001 is a retrospective, multi-center observational clinical investigation designed to establish the systemic safety and tolerability profile of a proprietary sub-nanometer micellar delivery platform. The platform utilizes a specialized 850-picometer hydrophilic emulsion, engineered to encapsulate lipophilic organic compounds (PIV-850 and legacy heterogeneous payloads) for intravenous administration.

In biopharmaceutical development, particle size is a primary determinant of safety and biological fate. By operating at a sub-1nm scale, the Pico IV platform seeks to bypass the "Delivery Wall"-the biological and mechanical barriers that typically lead to embolic risk or infusion-related reactions (CARPA) when oil-in-water emulsions are administered systemically. This study aims to provide the irrefutable human safety data required to support a 505(b)(2) Investigational New Drug (IND) application and a subsequent petition for Phase 1 safety waivers.

II. METHODOLOGICAL ARCHITECTURE AND BIAS MITIGATION To ensure the highest tier of evidence for FDA CDER review and rigorous biostatistical evaluation, the study employs a rigorous Consecutive Selection Algorithm.

Sampling Integrity: Each of the maximum 25 activated clinical sites is mandated to abstract a minimum of 15 and a maximum of 25 unique patient records. Abstractors must identify every patient exposure administered within the eligibility window (June 1, 2025 - April 15, 2026) and work chronologically backward from the end date. This 100% consecutive sampling protocol is mathematically designed to eliminate selection bias.

CMC Standardization: Data abstraction is strictly limited to patient exposures utilizing single-use sterile vials. This ensures the safety signals collected perfectly mirror the Sponsor's intended commercial Chemistry, Manufacturing, and Controls (CMC) sterile fill-finish protocols, neutralizing multi-use cross-contamination variables.

III. CLINICAL STRATIFICATION AND KINETIC SAFETY

The study abstracts granular data to assess the "Excipient Kinetic Safety Margin." The data is stratified to evaluate the following variables:

Formulation Evolution: Safety profiles are compared between the legacy heterogeneous formulations and the purified PIV-850 isolate to identify any variance in tolerability linked to trace neutral byproducts or minor organic components.

Administration Velocity: The study analyzes safety outcomes between "IV Push" and "IV Drip" protocols. This allows the Sponsor to determine the relationship between systemic infusion rates and the incidence of transient infusion-related reactions.

Dose-Escalation Safety: Retrospective dosing data capturing extreme supratherapeutic exposures to provide a clinical view of the dose-response safety curve in a diverse, real-world population.

IV. SAFETY MONITORING PARAMETERS

The abstraction process focuses on identifying both systemic and localized adverse events (AEs). Specific clinical markers include:

Complement Activation-Related Pseudoallergy (CARPA): Monitoring for flushing, dyspnea, and tachycardia to validate the immunological "stealth" of the 850-picometer micelle.

Vehicle Toxicity: Evaluating renal and hepatic markers (where available in charts) and general systemic tolerability to confirm the safety of the Polysorbate 80-based vehicle load.

Longitudinal Tolerability: Assessing the rate of infusion regimen completion versus early discontinuation due to intolerance.

V. REGULATORY AND STRATEGIC RATIONALE By formalizing up to 625 human exposures into a structured, de-identified database, PICO IV is leveraging Real-World Evidence (RWE) to establish an Excipient Kinetic Safety Bridge. This study functions as the definitive safety foundation for a 505(b)(2) IND application, demonstrating that the sub-nanometer architecture is both safe and stable in a broad human population.